0000950142-12-000415.txt : 20120215 0000950142-12-000415.hdr.sgml : 20120215 20120215191552 ACCESSION NUMBER: 0000950142-12-000415 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120213 FILED AS OF DATE: 20120215 DATE AS OF CHANGE: 20120215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ELMS STEVE CENTRAL INDEX KEY: 0001250195 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-52120 FILM NUMBER: 12617277 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 29TH FL CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: R&R ACQUISITION VI, INC CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 562590042 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 1270 AVENUE OF THE AMERICAS STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 973-635-4047 MAIL ADDRESS: STREET 1: 1270 AVENUE OF THE AMERICAS STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 4 1 es1200317_4-elms.xml OWNERSHIP DOCUMENT X0304 4 2012-02-13 0 0001368514 R&R ACQUISITION VI, INC NONE 0001250195 ELMS STEVE 888 SEVENTH AVE 30TH FL NEW YORK NY 10106 1 0 0 0 Common Stock 2012-02-13 4 A 0 2516855 A 2516855 I See Footnote On February 13, 2012, the issuer's wholly-owned subsidiary merged with ADMA Biologics, Inc., a privately-held Delaware corporation ("Former ADMA"). The issuer changed its name to ADMA Biologics, Inc. In connection with the merger and pursuant to the terms of the merger agreement, holders of Former ADMA's common stock received shares of the issuer's common stock and holders of options to purchase Former ADMA's common stock received options to purchase the same number of the issuer's common stock at the same exercise price. The reporting person indirectly acquired the issuer's securities in exchange for securities of Former ADMA. The issuer's shares of common stock are not currently listed on an exchange or quoted on the OTC Bulletin Board. The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, and Aisling Capital Partners, LLC ("Aisling Partners"), as general partner of Aisling GP. Mr. Elms is a managing member of Aisling and is a member of the Board of Directors of ADMA Biologics, Inc. Mr. Elms disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. /s/ Steve Elms 2012-02-15